Nectin-4 is a cell-adhesion molecule overexpressed in several tumor types, including breast, ovarian, lung, colorectal, pancreatic and urothelial cancer. Enfortumab vedotin (EV), an anti-Nectin-4 antibody-drug conjugate (ADC) has shown a good objective response rate in pretreated patients with advanced urothelial carcinoma. However, this effect has been linked to on-target skin toxicity.